ABC skutecznej terapii – 10 najważniejszych faktów o naproksenie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2023
Słowa kluczowe:
naproksen, mechanizm działania, terapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Naproksen to popularny niesteroidowy lek przeciwzapalny, przeciwbólowy i przeciwgorączkowy, którego mechanizm działania opiera się na hamowaniu syntezy prostaglandyn. Lek jest skuteczny w zwalczaniu bólu o zróżnicowanej etiologii, szczególnie w terapii reumatoidalnego zapalenia stawów. Wspiera także terapię zakażeń wirusowych i bakteryjnych, istotne znaczenie ma zdolność do depozycji w miejscu stanu zapalnego. W pracy omówiono zasady terapii, aktualne rekomendacje i możliwości terapeutyczne leku.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak , B. J. (2023). ABC skutecznej terapii – 10 najważniejszych faktów o naproksenie . Medycyna Faktów , 16(1(58), 53-57. https://doi.org/10.24292/01.MF.0123.09
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015; 8: 105-18. http://doi.org/10.2147/JPR.S75160.
2. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
3. Zhang H, Wu Y, Lin Z et al. Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15840. http://doi.org/10.1097/MD.0000000000015840.
4. Coşkun Ö, Karakaş A, Savaşci Ü et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
5. Kirshner JJ, McDonald MC 3rd, Kruter F et al. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer. 2018; 26(4): 1323-34. http://doi.org/10.1007/s00520-017-3959-2.
6. Bonnesen K, Schmidt M. Re-categorization of non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) according to clinical relevance: Abandoning the ´traditional NSAID´ terminology. Can J Cardiol. 2021: S0828-282X(21)00349-4. http://doi.org/10.1016/j.cjca.2021.06.014.
7. Prozzi GR, Cañás M, Urtasun MA et al. Riesgo cardiovascular de los antiinflamatorios no esteroideos [Cardiovascular risk of non-steroidal anti- inflammatory drugs]. Medicina (B Aires). 2018; 78(5): 349-355.
8. Tarp S, Bartels EM, Bliddal H et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta- analysis of randomized controlled trials. Arthritis Rheum. 2012; 64(11): 3511-21. http://doi.org/10.1002/art.34644.
9. Brutzkus JC, Shahrokhi M, Varacallo M. Naproxen. [Updated 2021 May 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.
10. Ong CK, Lirk P, Tan CH et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007; 5(1): 19-34.
11. Paglia MDG, Silva MT, Lopes LC et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One. 2021; 16(4): e0248866. http://doi.org/10.1371/journal.pone.0248866.
12. Mendell J, Lee F, Chen S et al. The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovascular Pharm. 2013; 62(2): 212-21. http://doi.org/10.1097/ FJC.0b013e3182970991.
13. Chong-Nguyen C, Dillinger JG, Spagnoli V et al. Naproxen as an alternat ive to aspirin for platelet inhibition in patients with cardiovascular disease requiring nonsteroidal anti-inflammatory drug? Arch Cardiovasc Dis Suppl. 2016; 8(3): 205.
14. Asadi M, Sayar S, Radmanesh E et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. Diabetes Metab Syndr. 2021; 15(6): 102319. http://doi.org/10.1016/j.dsx.2021.102319.
15. Khodavirdipour A. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective. Glob Med Genet. 2021; 8(2): 78-81. http://doi.org/10.1055/s-0041-1726461.
16. Terrier O, Dilly S, Pizzorno A et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593. http://doi.org/10.3390/molecules26092593.
17. Kiani P, Scholey A, Dahl TA et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021; 13(4): 558. http://doi.org/10.3390/v13040558.
18. Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020; 12(10): 1092. http://doi.org/10.3390/v12101092.
19. Adnet F, Slama Schwok A. Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection (ENACOVID). ClinicalTrials. gov (2020).
20.Robb CT, Goepp M, Rossi AG et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899-920. http://doi.org/10.1111/bph.15206.
21. Chiou WC, Hsu MS, Chen YT et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1): 147-53. http://doi.org/10.1080/14756366.2020.1850710.
22. Hui M, Carr A, Cameron S et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology. 2017; 56(7): e1-e20.
23. Weisman S. Naproxen for Post-Operative Pain. J Pharm Pharm Sci. 2021; 24: 62-70. http://doi.org/10.18433/jpps31629.
24. Moideen S, Anver PC, Uvais NA et al. Positive Naproxen Test in Psychogenic Fever. Prim Care Companion CNS Disord. 2021; 23(3): 20l02630. http://doi.org/10.4088/PCC.20l02630.
25. Han Mİ, Küçükgüzel ŞG. Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives. Mini Rev Med Chem. 2020; 20(13): 1300-10. http://doi.org/10.2174/1389557520666200505124922.
26. Grassi G, Cecchelli C, Vignozzi L et al. Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder. J Exp Pharmacol. 2021; 12: 695-706. http://doi.org/10.2147/JEP.S255375.
27. Kumar G, Madka V, Singh A et al. Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice. Neoplasia. 2021; 23(6): 574-83. http://doi.org/10.1016/j.neo.2021.05.010.
28. Mohammed A, Janakiram NB, Madka V et al. Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane--Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. Cancer Prev Res (Phila). 2019; 12(11): 751-62. http://doi.org/10.1158/1940-6207.CAPR-19-0312.
29. Athamneh T, Amin A, Benke E et al. Pulmonary drug delivery with aerogels: engineering of alginate and alginate-hyaluronic acid microspheres. Pharm Dev Technol. 2021; 26(5): 509-21. http://doi.org/10.1080/10837450.2021.1888979.
30. Chirikov VV, Walker C, Stephens JM et al. Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial. Clinicoecon Outcomes Res. 2021; 13: 409-20. http://doi.org/10.2147/CEOR.S280556.
2. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
3. Zhang H, Wu Y, Lin Z et al. Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15840. http://doi.org/10.1097/MD.0000000000015840.
4. Coşkun Ö, Karakaş A, Savaşci Ü et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
5. Kirshner JJ, McDonald MC 3rd, Kruter F et al. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer. 2018; 26(4): 1323-34. http://doi.org/10.1007/s00520-017-3959-2.
6. Bonnesen K, Schmidt M. Re-categorization of non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) according to clinical relevance: Abandoning the ´traditional NSAID´ terminology. Can J Cardiol. 2021: S0828-282X(21)00349-4. http://doi.org/10.1016/j.cjca.2021.06.014.
7. Prozzi GR, Cañás M, Urtasun MA et al. Riesgo cardiovascular de los antiinflamatorios no esteroideos [Cardiovascular risk of non-steroidal anti- inflammatory drugs]. Medicina (B Aires). 2018; 78(5): 349-355.
8. Tarp S, Bartels EM, Bliddal H et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta- analysis of randomized controlled trials. Arthritis Rheum. 2012; 64(11): 3511-21. http://doi.org/10.1002/art.34644.
9. Brutzkus JC, Shahrokhi M, Varacallo M. Naproxen. [Updated 2021 May 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.
10. Ong CK, Lirk P, Tan CH et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007; 5(1): 19-34.
11. Paglia MDG, Silva MT, Lopes LC et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One. 2021; 16(4): e0248866. http://doi.org/10.1371/journal.pone.0248866.
12. Mendell J, Lee F, Chen S et al. The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovascular Pharm. 2013; 62(2): 212-21. http://doi.org/10.1097/ FJC.0b013e3182970991.
13. Chong-Nguyen C, Dillinger JG, Spagnoli V et al. Naproxen as an alternat ive to aspirin for platelet inhibition in patients with cardiovascular disease requiring nonsteroidal anti-inflammatory drug? Arch Cardiovasc Dis Suppl. 2016; 8(3): 205.
14. Asadi M, Sayar S, Radmanesh E et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. Diabetes Metab Syndr. 2021; 15(6): 102319. http://doi.org/10.1016/j.dsx.2021.102319.
15. Khodavirdipour A. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective. Glob Med Genet. 2021; 8(2): 78-81. http://doi.org/10.1055/s-0041-1726461.
16. Terrier O, Dilly S, Pizzorno A et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593. http://doi.org/10.3390/molecules26092593.
17. Kiani P, Scholey A, Dahl TA et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021; 13(4): 558. http://doi.org/10.3390/v13040558.
18. Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020; 12(10): 1092. http://doi.org/10.3390/v12101092.
19. Adnet F, Slama Schwok A. Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection (ENACOVID). ClinicalTrials. gov (2020).
20.Robb CT, Goepp M, Rossi AG et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899-920. http://doi.org/10.1111/bph.15206.
21. Chiou WC, Hsu MS, Chen YT et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1): 147-53. http://doi.org/10.1080/14756366.2020.1850710.
22. Hui M, Carr A, Cameron S et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology. 2017; 56(7): e1-e20.
23. Weisman S. Naproxen for Post-Operative Pain. J Pharm Pharm Sci. 2021; 24: 62-70. http://doi.org/10.18433/jpps31629.
24. Moideen S, Anver PC, Uvais NA et al. Positive Naproxen Test in Psychogenic Fever. Prim Care Companion CNS Disord. 2021; 23(3): 20l02630. http://doi.org/10.4088/PCC.20l02630.
25. Han Mİ, Küçükgüzel ŞG. Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives. Mini Rev Med Chem. 2020; 20(13): 1300-10. http://doi.org/10.2174/1389557520666200505124922.
26. Grassi G, Cecchelli C, Vignozzi L et al. Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder. J Exp Pharmacol. 2021; 12: 695-706. http://doi.org/10.2147/JEP.S255375.
27. Kumar G, Madka V, Singh A et al. Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice. Neoplasia. 2021; 23(6): 574-83. http://doi.org/10.1016/j.neo.2021.05.010.
28. Mohammed A, Janakiram NB, Madka V et al. Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane--Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. Cancer Prev Res (Phila). 2019; 12(11): 751-62. http://doi.org/10.1158/1940-6207.CAPR-19-0312.
29. Athamneh T, Amin A, Benke E et al. Pulmonary drug delivery with aerogels: engineering of alginate and alginate-hyaluronic acid microspheres. Pharm Dev Technol. 2021; 26(5): 509-21. http://doi.org/10.1080/10837450.2021.1888979.
30. Chirikov VV, Walker C, Stephens JM et al. Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial. Clinicoecon Outcomes Res. 2021; 13: 409-20. http://doi.org/10.2147/CEOR.S280556.